NEW YORK (GenomeWeb News) – Sense Proteomic has spun out of parent firm Procognia to form a stand-alone company that will focus on using a protein array platform aimed at discovering biomarkers for cancer and auto-immune diseases.
 
The Maidenhead, UK-based company has turned to the private equity investment company Apax Partners for financial backing.
 
Financial details of the investment and the spin out were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.